Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
of other biotech firms
|
| gptkbp:advertising |
focused on niche markets
|
| gptkbp:budget |
published annually
|
| gptkbp:businessModel |
focused on innovation
focused on strategic partnerships |
| gptkbp:CEO |
Gil_Beyen
|
| gptkbp:challenges |
faced in the industry
|
| gptkbp:clinicalTrials |
Phase 3 trials
published in medical journals established worldwide conducted globally ongoing for new therapies achieved in recent years ongoing for various cancers |
| gptkbp:collaborations |
with other biotech firms
with pharmaceutical companies with universities with international researchers |
| gptkbp:community_engagement |
involved in patient advocacy
|
| gptkbp:community_service |
measured in trials
|
| gptkbp:competitors |
conducted regularly
|
| gptkbp:enrollment |
targeted in studies
|
| gptkbp:evaluates |
demonstrated in clinical studies
|
| gptkbp:feedback |
monitored closely
|
| gptkbp:focus |
developing treatments for cancer
|
| gptkbp:founded |
2004
|
| gptkbp:founder |
gptkb:Yves_Lévy
|
| gptkbp:funding |
sourced from grants and investments
|
| gptkbp:future_plans |
expand product offerings
positive based on pipeline |
| gptkbp:global_presence |
in multiple countries
|
| gptkbp:headquarters |
gptkb:Lyon,_France
|
| https://www.w3.org/2000/01/rdf-schema#label |
Erytech Pharma
|
| gptkbp:investmentFocus |
managed by a dedicated team
from venture capital institutional and private |
| gptkbp:market |
oncology
|
| gptkbp:partnerships |
with healthcare providers
with various research institutions |
| gptkbp:patentCitation |
held for its technologies
strategy in development |
| gptkbp:products |
driven by patient needs
ERY-ASP ERY-ASP_for_acute_lymphoblastic_leukemia |
| gptkbp:publications |
produced by its researchers
|
| gptkbp:regulatoryCompliance |
for its products
ensured through protocols filed with health authorities |
| gptkbp:relatedEvent |
held regularly
|
| gptkbp:research_areas |
hematology
pursued actively. |
| gptkbp:research_focus |
metabolic diseases
|
| gptkbp:revenue |
varies by year
|
| gptkbp:safety_features |
assessed in trials
|
| gptkbp:social_responsibility |
initiatives in place
|
| gptkbp:stockExchange |
gptkb:Euronext_Paris
|
| gptkbp:supportRole |
established for guidance
|
| gptkbp:targetMarket |
strategies developed for new regions
|
| gptkbp:team |
composed of industry experts
|
| gptkbp:technology |
erythrocyte encapsulation
to commercial partners |
| gptkbp:tributaryOf |
multiple drug candidates
|